Tag: Investment
-
Cellestial Health Presents at the Venture Summit West, California
18th of June 2026; Mountain View, California, USACellestial Health, an innovative pharmaceutical development company offering a paradigm shift approach to Parkinson’s treatments, announces its selection and participation at the 2025 Venture Summit West, which took place June 16–17, 2025 at the Computer History Museun in Mountain View, Silicon Valley. Hosted by youngStartup Ventures, the summit is recognized as…
-
Cellestial Health Joins ET Capital Portfolio and Secures Strategic Support
27th of April 2026; Cambridge, UK Cellestial Health, a biopharmaceutical company developing a new class of drugs for Parkinson’s which affects over 10 million people in the world, is pleased to have recently joined the portfolio of the Cambridge Venture Index Fund (CVIF) of ET Capital – a fund supporting diversified deep science companies spinning out…
-
BioSeed 2026: What Matters
On Monday 19th of January, the Cellestial Team attended BioSeed by OBN to re-connect with the London life sciences community and share why our approach to astrocytic network restoration matters in Parkinson’s. ✦ For brain cells, we are looking to reduce the burden of abnormal protein aggregates and inflammation via a novel mechanism✦ For people…
-
Genesis 2025: Current State of Field and De-Risking
The annual Genesis 2025 conference by One Nucleus on Tuesday 3rd of December brought the Life Sciences community together once again, this time under the theme of “𝘔𝘢𝘹𝘪𝘮𝘪𝘴𝘪𝘯𝘨 𝘙𝘦𝘵𝘶𝘳𝘯𝘴 𝘰𝘯 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯”. Dr Nat Hastings delivered a concise presentation on the latest developments at Cellestial Health alongside an array of brilliant companies including LYEONS Neurotech, GutSee Health, and ikarovec; and Martyn Postle actively participated in the networking sessions. The field…
-
Cellestial Health officially opens Seed funding round
On Monday 17th of November, at the LSX Investival 2025 and at the start of the Jeffries week in London, Dr Nat Hastings (CEO) of Cellestial Health has officially opened the Seed fundraise. This follows on from a strong year post-Pre-Seed funding, featuring:✦ Proof-of-concept studies in disease-relevant models✦ New academic and charity collaborations✦ Established pipeline…
-
OBN BioSeed: Raising Awareness
On Monday 9th of June, Dr Nat Hastings presented the developments and plans of Cellestial Health at the annual #BioSeed event, where pitches are delivered by companies looking for Seed funding. At the moment, Cellestial is only preparing for its Seed funding round. What are the benefits of our early discussion with the investor community?…
-
Cellestial Health Closes Pre-Seed Equity Round
Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease. The equity round was led by Zinc VC, with the latest investment…
-
Making it Happen: a Path to Commercialisation
What does it take to successfully commercialise healthcare innovation? Excellent science is key, but it is not enough. Many factors must converge for a therapeutic discovery to find its way to practical applications: Dr Chloe Hall spoke with Dr Nat Hastings about translatability of Parkinson’s models and specific challenges that emerging companies face in this…
-
Zinc VC and Cellestial Health: Pioneering Brain Therapeutics
How the vision of Zinc VC aligns with the mission of Cellestial Health to pioneer new brain therapeutics and improve global health equity? Find out in the new blog and press-release: https://www.zinc.vc/blog/introducing-cellestial-health-pioneering-novel-therapeutics-for-brain-disorders https://www.linkedin.com/posts/zincvc_introducing-cellestial-health-pioneering-activity-7270742302254415873-trXT